Website
News25/Ratings10
News · 26 weeks22-100%
2025-10-262026-04-19
Mix1190d
- SEC Filings4(36%)
- Other3(27%)
- Insider3(27%)
- Analyst1(9%)
Latest news
25 items- SECAmendment: SEC Form 10-K/A filed by Innoviva Inc.10-K/A - Innoviva, Inc. (0001080014) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)
- SECSEC Form DEF 14A filed by Innoviva Inc.DEF 14A - Innoviva, Inc. (0001080014) (Filer)
- SECInnoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Innoviva, Inc. (0001080014) (Filer)
- SECSEC Form 10-K filed by Innoviva Inc.10-K - Innoviva, Inc. (0001080014) (Filer)
- INSIDERChief Financial Officer Basso Stephen covered exercise/tax liability with 1,244 shares, decreasing direct ownership by 2% to 50,013 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Executive Officer Raifeld Pavel covered exercise/tax liability with 2,986 shares, decreasing direct ownership by 2% to 159,290 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Accounting Officer Zhen Marianne covered exercise/tax liability with 2,460 shares, decreasing direct ownership by 5% to 45,877 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- PRInnoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 10:00 a.m. E.T. The conference will be held virtually. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentati
- ANALYSTBTIG Research initiated coverage on Innoviva with a new price targetBTIG Research initiated coverage of Innoviva with a rating of Buy and set a new price target of $35.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)
- PRU.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and AdolescentsFDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea across five countries. NUZOLVENCE is one of the first new treatments approved by the FDA for uncomplicated urogenital gonorrhea in nearly two decades. Gonorrhea affects more than 82 million people worldwide each year and is the second most reported bacterial STI in the United States.1,2 Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a
- PRInnoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital GonorrheaPhase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive study results are a significant milestone in the development of a first-in-class single-dose, oral antibiotic against gonorrhea, including infections caused by drug-resistant Neisseria gonorrhoeae, an urgent public health threat and high-priority pathogen. Gonorrhea is the second most reported bacterial STI in the United States, with resistance to first-line treatment emerging.1,2 Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced the publication of positive res
- PRInnoviva to Participate in the 37th Annual Piper Sandler Healthcare ConferenceInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 2, 2025 at 4:30 p.m. Eastern Time. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentations-events. An archived replay
- INSIDERChief Financial Officer Basso Stephen was granted 604 shares and covered exercise/tax liability with 237 shares, increasing direct ownership by 0.72% to 51,257 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Accounting Officer Zhen Marianne covered exercise/tax liability with 992 shares, decreasing direct ownership by 2% to 48,337 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Financial Officer Basso Stephen was granted 27,609 shares, increasing direct ownership by 119% to 50,890 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERLarge owner Raifeld Pavel was granted 112,296 shares, increasing direct ownership by 225% to 162,276 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- SECSEC Form 10-Q filed by Innoviva Inc.10-Q - Innoviva, Inc. (0001080014) (Filer)
- SECInnoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Innoviva, Inc. (0001080014) (Filer)
- PRInnoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company ProgressGenerated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth Strengthened product portfolio with U.S. launch of ZEVTERA® Announced $125 million share repurchase program Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achieve
- PRAntheia Appoints Eric d'Esparbes as Chief Financial Officerd'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif., Oct. 21, 2025 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer. d'Esparbes will oversee Antheia's financial strategy and operations as the company advances its next phase of commercialization and unlocks its U.S. manufacturing capabilities. His appointment comes at a critical point in Antheia's trajectory, following the company's $56 million Series C fundraise in June of this year and the launch of its first commercia
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)
- PRInnoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025Highlights include an oral presentation of a subset analysis from the Phase 3 clinical trial of zoliflodacin, an investigational single-dose oral treatment for uncomplicated gonorrhea due to Neisseria gonorrhoeae Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that it will deliver data from six presentations at IDWeek 2025, including clinical data, pharmacokinetic-pharmacodynamic (PK-PD) analyses, and microbiologic surveillance from its growing portfolio of antibiotics and critical care medicines. IDWeek will be held in Atlanta, GA, from October 19-22, 2025. Highlights include two oral presentations: a subset analysis from the Phase 3 trial